Latest News

Sophie Holmes, PhD, assistant professor of psychiatry, and Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to WTNH - News 8 about their clinical trials that use the anesthetic ketamine to treat depression in people with Parkinson's disease.

Older patients who receive electroconvulsive therapy (ECT) for treatment of mood disorders have lower risk of mortality and greater protection against short-term risk of suicide, according to a Yale study.

Sina Nikayin, MD, assistant professor of psychiatry, and Robert Ostroff, MD, co-medical director of the Interventional Psychiatry Service at Yale New Haven Psychiatric Hospital, are co-authors of a paper in Journal of the Neurological Sciences that describes interventional psychiatry training at Yale New Haven Psychiatric Hospital.

Two Yale Department of Psychiatry researchers have been awarded a $2 million grant from The Michael J. Fox Foundation for Parkinson’s Research to conduct the first clinical trial of ketamine to treat depression in people with Parkinson’s disease.

How safe is the anesthetic ketamine in the treatment of chronic depression? Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry and Director of the Yale Depression Research Program, offered perspective in a recent New York Times article.

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to InStyle about how ketamine is being used to treat depression.

Ketamine, the anesthetic and pain-relieving drug sometimes used for hallucinogenic effects, could revolutionize mental health care. Yet, how and why the drug relieves depression symptoms is still clouded in mystery."Like many advances in psychiatry, the clinical breakthrough occurred before we understood how it worked to alleviate depression," John H. Krystal, MD, Chair of the Yale Department of Psychiatry, told Verywell via email.

Wherever constant stress lives, so too does its more agitated and debilitating cousin: anxiety. About 31% of Americans will experience an anxiety disorder at some point in their lives. What’s more, anxiety often goes hand-in-hand with depression.

Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, writes in Psychiatric Times about the drug esketamine, approved by the U.S. Food and Drug Administration last year as the first rapid-acting therapy for treatment-resistant depression.